Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. November 07, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.01865 Journal of Clinical Oncology - published online before print November 7, 2023 PMID: 37935102 Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma Ingo K. Mellinghoff , MD1,2xIngo K. MellinghoffSearch for articles by this author Show More 1Former Associate Editor, Journal of Clinical Oncology, Alexandria, VA2Department of Neurology, Memorial Sloan Kettering Cancer Center, New York City, NY https://doi.org/10.1200/JCO.23.01865 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 2009, Friedman et al1 reported the activity of bevacizumab in the treatment of recurrent glioblastoma. Although the initial enthusiasm regarding the use of bevacizumab in glioblastoma has faded over the years, because of its lack of effect on overall survival, the Friedman et al1 trial remains a milestone in the quest for molecularly targeted therapies for glioblastoma. Companion Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma